In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $5.11.
Arias covers the Healthcare sector, focusing on stocks such as Danaher, Illumina, and 10x Genomics. According to TipRanks, Arias has an average return of -8.3% and a 40.00% success rate on recommended stocks.
Maravai Lifesciences Holdings has an analyst consensus of Strong Buy, with a price target consensus of $11.00, which is an 115.26% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $16.62 and a one-year low of $4.52. Currently, Maravai Lifesciences Holdings has an average volume of 2.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Maravai Lifesciences Holdings (MRVI) Company Description:
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company’s segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers’ research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Read More on MRVI:
